m3u

Dr. Steven Radowitz

This week Dr. Drew talks to Dr. Steven Radowitz, the Chief Medical Officer at the Nushama Psychedelic Wellness Center, a pioneer in therapy. Together, they delve into the pressing me

m3u

Expanding Screening, Improving Treatment Acceptance, and Optimizing Outcomes for Patients w

Host: Annie Levesque, MD, MSc Guest: Ethan A. Cowan, MD Alcohol use disorder, or AUD, is a rising health crisis that often goes undiagnosed. And many patients that are diagnosed with AUD do not recei

m3u

Maximizing Benefit With the Expanding Options for Gastric Cancer: Patient Selection and Man

Guest: James M. Cleary, MD, PhD Guest: Kathleen Madden, FNP, MSN, AOCNP, APHN This on-demand features an expert case discussion on the current landscape of gastric cancer, from patient selection to t

m3u

Addressing the Unmet Need in HER2-Positive Advanced Solid Tumors: Exploring Response Rates

Guest: Susana Banerjee, MBBS, MA, FRCP, PhD HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effect

m3u

Targeting HER2 in Advanced Solid Tumors: A Comprehensive Understanding of the Rationale and

Guest: Shubham Pant, MD, MBBS HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treatin

m3u

Testing for Solid Tumors: Tissue and Liquid Biopsy Approaches Using NGS Technologies for cf

Guest: Kathleen Moore, MD, MS HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treatin

m3u

Management Strategies for Adverse Events (TEAEs) in HER2-Altered Advance

Host: Kathleen Moore, MD, MS Guest: Brad McGregor, MD HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therap

m3u

Cervical Cancer: HER2-Targeted ADCs – Current Status and Future Directions

Guest: Kathleen Moore, MD, MS HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treatin

m3u

Ovarian Cancer: Advances in HER2-Targeted ADCs

Guest: Kathleen Moore, MD, MS HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treatin

m3u

Endometrial Cancer: HER2-Targeted ADCs: A Promising Approach to Address Unmet Needs

Guest: Kathleen Moore, MD, MS HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treatin

m3u

Biliary Tract and Pancreatic Cancer: HER2-Targeted ADCs for Cancers

Guest: Shubham Pant, MD, MBBS HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treatin

m3u

Bladder Cancer: HER2-Targeted ADCs for Genitourinary Cancers

Guest: Brad McGregor, MD HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating oth

m3u

ASCO/ESMO 2023 Roundtable: the Latest Advances in HER2-Targeted Therapy for

Host: Kathleen Moore, MD, MS Guest: Susana Banerjee, MBBS, MA, FRCP, PhD Guest: Shubham Pant, MD, MBBS HER2-targeted treatments have been extensively researched and approved in breast, gastric, and n

m3u

Taking the Approach to Mycophenolate Risk Mitigation, Mycophenolate Risk M

Guest: Cara Dolin, MD Guest: Jennifer Simpson Guest: Diana Girnita, MD ,PhD Explore this video roundtable featuring an panel of experts discussing a woman’s journey with mycophenola

m3u

Challenges in Recognizing and Diagnosing Narcolepsy

Host: Kevin Trice, MD This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses

m3u

Life’s Essential 8: Healthy Sleep With Narcolepsy

Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy.

m3u

Epidemiology of Cardiovascular Disease In Narcolepsy

Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy.

m3u

Life’s Essential 8 Diet Paradigm: The Narcolepsy Connection

Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy.

m3u

Treatment Options for the Management of Narcolepsy

Host: Ana C. Krieger, MD This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addres

m3u

Practical Approach to Incorporation of Oxybates Into Clinical Practice

Host: Kevin Trice, MD Host: Ana C. Krieger, MD This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy.

m3u

Are Oxybates Safe in Narcolepsy Patients?

Host: Kevin Trice, MD Host: Ana C. Krieger, MD This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy.

m3u

Expert Consensus on How Oxybates Influence Cardiovascular Risk in Narcolepsy Patients

Host: Kevin Trice, MD Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individ

m3u

Challenges in Recognizing and Diagnosing Idiopathic Hypersomnia

Host: Alcibiades J. Rodriguez, MD, FAASM The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH

m3u

Idiopathic Hypersomnia Insights: A Diagnostic Case Study

Host: Alcibiades J. Rodriguez, MD, FAASM The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH

m3u

Idiopathic Hypersomnia and Cardiovascular Health: Too Much of a Good Thing?

Host: Logan Schneider, MD The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledgin

m3u

Evaluating and Promoting Health in Idiopathic Hypersomnia: Beyond Sleepy

Host: Logan Schneider, MD The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledgin

m3u

Patient Testimonial: A Day In the Life of an Idiopathic Hypersomnia Patient

Host: Logan Schneider, MD Host: Diana Kimmel The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia

m3u

Evolving Treatment Paradigms in Idiopathic Hypersomnia

Host: Matthew Davis, MD The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging

m3u

Professional of Clinically Validated Tools Used to Monitor Response to Trea

Host: Matthew Davis, MD Host: Alcibiades J. Rodriguez, MD, FAASM The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Id

m3u

Evidence-based Discussion of the New and Emerging Treatment Strategies for Idiopathic Hyper

Host: Matthew Davis, MD Host: Logan Schneider, MD The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypers

m3u

Which Comes First? The Stimulant or the Oxybate?

Host: Matthew Davis, MD Host: Alcibiades J. Rodriguez, MD, FAASM The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Id

m3u

The Gut Microbiome: An Evidence-Based Approach to Managing Recurrent C difficile Infection

Guest: James M. Cleary, MD, PhD Guest: Kathleen Madden, FNP, MSN, AOCNP, APHN This on-demand features an expert case discussion on the current landscape of gastric cancer, from patient selection to t3